09:26 AM EDT, 08/05/2025 (MT Newswires) -- Vera Therapeutics ( VERA ) reported a Q2 net loss Tuesday of $1.20 per diluted share, widening from a loss of $0.62 a year earlier.

Analysts polled by FactSet expected a loss of $0.82 per share.

The clinical-stage biopharmaceutical company did not report any revenue for the quarter.

The company reported cash and cash equivalents of $556.8 million as of June 30.

Vera Therapeutics ( VERA ) expects its current cash position, combined with its undrawn debt facility, to be sufficient to fund operations through a potential approval and US commercial launch of its atacicept product.